Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Ojala VK et al.
Molecular Oncology, 2025
Genetic analysis of ERBB4 gene in Chinese patients with amyotrophic lateral sclerosis: a single-center study and systematic review of published literature.
Shen D et al.
Frontiers in Aging Neuroscience, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM et al.
Cancers, 2024
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM et al.
Pharmacological Reviews, 2022
Analysis of ERBB4 Variants in Amyotrophic Lateral Sclerosis Within a Chinese Cohort.
Wang F et al.
Frontiers in Neurology, 2022
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
Ak M et al.
Genes, 2021
BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas.
Colombino M et al.
Journal of Clinical Medicine, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.
Miyoshi T et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C et al.
Methods in Molecular Biology (clifton, N.j.), 2014
The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
Zhou QM et al.
Chinese Journal of Cancer, 2013
A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U et al.
Cell Cycle (georgetown, Tex.), 2010